Related Experiment Video
Updated: Oct 20, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors
1Laboratory of Biologic Cancer Therapy, Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA.psgoedegeb@bics.bwh.harvard.edu
Abstract:
Recent progress in tumor genetics, tumor biology, and tumor immunology has renewed interest in the development of tumor vaccines. Unlike the previous generation of vaccines that consisted of the patient's own tumor cells in some form, the new vaccines contain defined peptides or genes with a known function. In order to induce a potent and long-lasting cell-mediated antitumor response, viral as well as nonviral vectors have been explored as vehicles for gene delivery. Both types of vectors have shown encouraging results in animal models. However, because of the many possible vectors that have been designed, it may be too early to say which type of vector is most efficient in the human. Clearly viral vectors have a higher transduction efficiency than most nonviral delivery systems. A drawback is that viral vectors may be toxic or immunogenic. Current research focuses on enhancing the targeting and specificity of both viral and nonviral vectors and control of transgene expression levels. Clinical studies using a variety of both viral and nonviral vectors have begun, and the results are forthcoming.
Insights
New tumor vaccines utilize defined peptides or genes for enhanced antitumor responses. Viral and nonviral vectors show promise in preclinical studies, with ongoing research focusing on vector optimization for clinical trials.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Recent advancements in tumor genetics, biology, and immunology have revitalized interest in therapeutic cancer vaccines.
- Next-generation tumor vaccines differ from earlier approaches by incorporating specific peptides or genes with known functions, aiming for more targeted therapeutic effects.
Purpose of the Study:
- To review the progress and challenges in developing novel tumor vaccines.
- To explore the role of viral and nonviral vectors in delivering genetic material for cancer immunotherapy.
- To discuss current research directions in optimizing vector efficiency, targeting, and safety for clinical application.
Main Methods:
- Review of current literature on tumor vaccine development.
- Analysis of viral and nonviral gene delivery systems for cancer immunotherapy.
- Examination of preclinical and emerging clinical data on vector-based tumor vaccines.
Main Results:
- Both viral and nonviral vectors have demonstrated potential in animal models for inducing cell-mediated antitumor immunity.
- Viral vectors generally exhibit higher transduction efficiency but may pose risks of toxicity and immunogenicity.
- Nonviral vectors offer a potentially safer alternative, though often with lower efficiency.
Conclusions:
- The choice of vector (viral vs. nonviral) for tumor vaccines is still under investigation, with ongoing efforts to balance efficiency and safety.
- Future research is focused on improving vector targeting, specificity, and controlled transgene expression.
- Clinical trials are underway to evaluate the efficacy and safety of various vector-based tumor vaccines in humans.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:51Vaccinations